Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > REGULATORY
REGULATORY
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
- Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
- Japan to Decide on COVID Health Funding from October, Assuming Shift to Normalcy Next Spring: Minister
September 1, 2023
- MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
- 8 New Cases of Unintentional Xocova Use Among Pregnant Patients, Adding Up to 15
August 31, 2023
- Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
- MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
- MHLW to Unveil Draft of 2nd Package Strategy for SaMD on Sept. 6
August 31, 2023
- MHLW to Issue Development Requests for New Uses of Rituxan, Truvada, and More
August 31, 2023
- Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
- MHLW Orders Label Revisions for Prazaxa, Smyraf, and More
August 30, 2023
- MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
August 30, 2023
- Label Revisions Ordered for CAR-T Therapies on Out-of-Spec Products
August 30, 2023
- Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
- Kazunari Asanuma to Lead MHLW Health Policy Bureau
August 29, 2023
- MHLW to Seek Funds for Survey to Streamline Generic Manufacturing: FY2024 Request
August 28, 2023
- MHLW to Book Budget to Launch Regulatory Advisory Center for Pediatric, Orphan Meds for FY2024
August 28, 2023
- MHLW to Seek 33.7 Trillion Yen Budget for FY2024
August 28, 2023
- Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
August 28, 2023
- Shunichi Kuryu to Take Helm at New Infectious Disease Agency
August 28, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…